Axogen, Inc. 2021 Form 10-K Summary
Business context and reporting period
Axogen develops and commercializes products for peripheral nerve repair, led by Avance Nerve Graft and Axoguard products. This 10-K reports the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter results. Comparisons below are with fiscal 2020.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $127.4 million | $112.3 million |
| Gross profit / margin | $104.4 million / 82.0% | $90.7 million / 80.8% |
| Operating loss | $25.4 million | $23.2 million |
| Net loss / diluted loss per share | $27.0 million / $0.65 | $23.8 million / $0.60 |
| Cash used in operating activities | $13.4 million | $9.6 million |
| Cash used in investing activities | $23.6 million | $17.0 million |
Revenue grew 13.4%, driven by approximately 8% higher unit volume and a roughly 5% net contribution from price and product mix. The company ended 2021 with $32.8 million of cash and equivalents, $51.3 million of investments, and $6.3 million of restricted cash. Cash and investments totaled $84.1 million, excluding restricted cash. Working capital was $102.8 million and the current ratio was 5.2x, versus $122.4 million and 6.4x, respectively, at year-end 2020.
Gross margin improved despite a $1.4 million Avive-related inventory and production-cost charge. Total operating expenses rose 14.0% to $129.8 million, including R&D of $24.2 million, up 35.5%. The company reported no income tax expense or benefit, as deferred tax benefits were fully reserved.
At year-end, Oberland debt principal was $50.0 million, with a net carrying amount of $44.8 million after discounts and fees; debt derivative liabilities were $5.6 million. The facility bears interest at a minimum 9.5%, plus revenue participation payments that management estimates add about 1.0% annually to the outstanding loan amount. The debt is secured by substantially all company assets and includes covenants and potential acceleration provisions.
Material changes versus FY 2020
- Revenue increased $15.1 million, but net loss widened by $3.2 million and operating loss by $2.2 million.
- Gross margin rose 1.2 percentage points. FY 2020 margin had been reduced by idle-facility costs and inventory write-downs; FY 2021 included the Avive-related charge.
- Operating cash use increased $3.8 million, reflecting working-capital changes and the higher net loss. Inventory increased to $16.7 million from $12.5 million.
- Investing cash outflows increased primarily because of the Axogen Processing Center (APC) renovation. Property and equipment rose to $62.9 million from $38.4 million.
- Axogen drew a second $15 million tranche of Oberland debt in June 2021, bringing gross principal to $50 million.
- Active accounts rose 6.5% to 951; core accounts, defined as accounts purchasing at least $100,000 over 12 months, rose 9.3% to 294.
Outlook, risks, contingencies, and unusual items
- Management said available cash, investments, and expected product-sale cash flows should fund operations for at least the next 12 months. It gave no specific revenue or earnings guidance in the supplied filing text.
- Management expected RECON trial top-line data in Q2 2022 and an Avance BLA submission in 2023. RECON follow-up was completed in August 2021; outcomes were not yet available at filing. Avance remains commercially distributed under FDA enforcement discretion and a transition plan; an adverse regulatory decision or unsuccessful BLA could prevent continued sales.
- Avive market availability was voluntarily suspended effective June 1, 2021 while Axogen discusses regulatory classification with the FDA. The filing says the suspension was not prompted by safety or product concerns. Avive had represented about 5% of revenue through Q2 2021; there was no Avive revenue in H2. Return timing and feasibility are uncertain.
- The APC facility was expected to undergo renovation followed by validation and certification, with tissue processing anticipated in early 2023. Management forecast approximately $19.3 million of additional spending in 2022 and $1.7 million in 2023. State and local grants include job-creation milestones and clawback provisions.
- A notable debt uncertainty concerns Oberland’s make-whole payment calculation. Axogen estimates a $68,000 payment on the first tranche at scheduled maturity under its interpretation, but estimates that an alternative interpretation could produce payments of up to approximately $13 million on the first tranche and $5 million on the second; prepayment could increase the amounts. The parties’ differing interpretation is disclosed in the filing.
- A securities class action was dismissed with prejudice in March 2021, and the plaintiff appealed; oral argument was scheduled for March 8, 2022. The company disputes the allegations and says the potential loss cannot be reasonably estimated. A separate derivative action was voluntarily dismissed without prejudice in November 2021.
- Key business risks include COVID-related hospital staffing and procedure disruptions, dependence on a small number of products, donor-tissue supply and third-party manufacturing, reimbursement and market adoption, regulatory compliance, and execution of the APC transition. The company reported effective internal controls; Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether RECON results support the planned Avance BLA, whether the FDA accepts the data and manufacturing controls, and whether the 2023 submission timeline remains achievable.
- Progress on FDA discussions for Avive, and whether it can return to market and contribute revenue.
- APC construction, validation, regulatory readiness, total remaining cost, and ability to transition processing before the CTS agreement ends in December 2023.
- Operating cash burn, inventory growth and write-down assumptions, and whether revenue growth can support improved cash generation.
- The Oberland make-whole interpretation, future debt-service and revenue-participation cash costs, covenant compliance, and liquidity available after restricted cash.
- Developments in the securities appeal, reimbursement coverage, hospital procedure volumes, and supply or staffing constraints.